当前位置: 首页 >> 检索结果
305. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
作者: Ki Hong Choi.;Yong Hwan Park.;Jong-Young Lee.;Jin-Ok Jeong.;Chan Joon Kim.;Kyeong Ho Yun.;Han Cheol Lee.;Kiyuk Chang.;Mahn-Won Park.;Jang-Whan Bae.;Joon-Hyung Doh.;Byung Ryul Cho.;Hee-Yeol Kim.;Weon Kim.;Ung Kim.;Seung-Woon Rha.;Young Joon Hong.;Hyun-Jong Lee.;Sung Gyun Ahn.;Doo-Il Kim.;Jang Hyun Cho.;Sung Ho Her.;Doo Soo Jeon.;Seung Hwan Han.;Jin-Bae Lee.;Cheol Whan Lee.;Danbee Kang.;Joo Myung Lee.;Taek Kyu Park.;Jeong Hoon Yang.;Soo-Youn Lee.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.; .
来源: Lancet. 2025年405卷10486期1252-1263页
The optimal strategy for long-term antiplatelet maintenance for patients who underwent percutaneous coronary intervention (PCI) remains uncertain. This study aimed to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI with drug-eluting stents.
306. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
作者: William F Fearon.;Frederik M Zimmermann.;Victoria Y Ding.;Kuniaki Takahashi.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavičius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angerås.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.
来源: Lancet. 2025年405卷10488期1481-1490页
Long-term outcomes following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) might be changing because of improved techniques and better medical therapy. This final prespecified analysis of the Fractional Flow Reserve (FFR) versus Angiography for Multivessel Evaluation (FAME) 3 trial aimed to reassess their comparative effectiveness at 5 years.
307. Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
作者: Xinyang Hu.;Jinlong Zhang.;Seokhun Yang.;Jun Jiang.;Xiaoping Peng.;Dongsheng Lu.;Yibin Pan.;Lijun Guo.;Jilin Li.;Wenming He.;Hao Zhou.;Jun Pu.;Jinyu Huang.;Fan Jiang.;Qiang Liu.;Daqing Song.;Liang Lu.;Zhenfeng Cheng.;Bin Yang.;Jianliang Ma.;Peng Chen.;Shiqiang Li.;Zhaohui Meng.;Lijiang Tang.;Yongzhen Fan.;Eun-Seok Shin.;Shengxian Tu.;Chang-Wook Nam.;William F Fearon.;Bon-Kwon Koo.;Jian'an Wang.; .
来源: Lancet. 2025年405卷10488期1491-1504页
Revascularisation decisions based on angiography-derived fractional flow reserve (FFR) or optimisation of stent implantation with intravascular ultrasound yield superior clinical outcomes compared with percutaneous coronary intervention (PCI) guided by angiography alone. However, the differences in outcomes when a single approach is used for both purposes remain unclear. We aimed to assess the non-inferiority of angiography-derived FFR versus intravascular ultrasound guidance in terms of clinical outcomes at 12 months in patients with angiographically significant stenosis.
308. Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
作者: Ajay J Kirtane.;Philippe Généreux.;Bruce Lewis.;Richard A Shlofmitz.;Suhail Dohad.;Jithendra Choudary.;Thom Dahle.;Andres M Pineda.;Kendrick Shunk.;Akiko Maehara.;Alexandra Popma.;Bjorn Redfors.;Ziad A Ali.;Mitchell Krucoff.;Ehrin Armstrong.;David E Kandzari.;William O'Neill.;Carlye Kraemer.;Krista M Stiefel.;Denise E Jones.;Jeff Chambers.;Gregg W Stone.; .
来源: Lancet. 2025年405卷10486期1240-1251页
Coronary artery calcification is common among patients undergoing percutaneous coronary intervention (PCI), and severe coronary artery lesion calcification is associated with increased procedural complexity, stent under-expansion, and high rates of intraprocedural complications and out-of-hospital adverse events. Whether calcium ablation before stent implantation can mitigate these adverse events is not currently established. We aimed to prospectively compare orbital atherectomy with a balloon angioplasty-based strategy before stent implantation for the treatment of severely calcified coronary lesions.
313. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
作者: Marc P Bonaca.;Andrei-Mircea Catarig.;Kim Houlind.;Bernhard Ludvik.;Joakim Nordanstig.;Chethana Kalmady Ramesh.;Neda Rasouli.;Harald Sourij.;Alex Videmark.;Subodh Verma.; .
来源: Lancet. 2025年405卷10489期1580-1593页
Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally. Few therapies improve functional capacity and health-related quality of life in people with lower limb peripheral artery disease. We aimed to evaluate whether semaglutide improves function as measured by walking ability as well as symptoms, quality of life, and outcomes in people with peripheral artery disease and type 2 diabetes.
314. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Lauren C Tindale.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Kelly L Warfield.;Roshan Ramanathan.;Jorge T Caso.;Victoria A Jenkins.;Patrick Ajiboye.;Lisa Bedell.; .
来源: Lancet. 2025年405卷10487期1343-1352页
Chikungunya disease is a growing global public health concern. Vimkunya (previously chikungunya virus virus-like particle vaccine, previously PXVX0317) is a single-dose, pre-filled syringe for intramuscular injection. Here, we report safety, tolerability, and immunogenicity data for Vimkunya versus placebo in healthy adolescents and adults aged 12-64 years, and evaluate lot-to-lot consistency.
315. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.
作者: Antoni Castells.;Enrique Quintero.;Luis Bujanda.;Susana Castán-Cameo.;Joaquín Cubiella.;José Díaz-Tasende.;Ángel Lanas.;Akiko Ono.;Miquel Serra-Burriel.;Eladio Frías-Arrocha.;Cristina Hernández.;Rodrigo Jover.;Montserrat Andreu.;Fernando Carballo.;Juan Diego Morillas.;Dolores Salas.;Raquel Almazán.;Inmaculada Alonso-Abreu.;Jesús M Banales.;Vicent Hernández.;Isabel Portillo.;Mercedes Vanaclocha-Espí.;Mariola de la Vega.; .
来源: Lancet. 2025年405卷10486期1231-1239页
Colonoscopy and the faecal immunochemical test are accepted strategies for colorectal cancer screening in the average-risk population (ie, people aged ≥50 years without personal or family history of colorectal cancer). In this trial, we aimed to compare whether invitation to screening with faecal immunochemical test was non-inferior to colonoscopy in a screening programme.
316. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Lauren C Tindale.;Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Roshan Ramanathan.;Victoria A Jenkins.;Lisa Bedell.;Patrick Ajiboye.; .
来源: Lancet. 2025年405卷10487期1353-1361页
Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death.
|